Upadacitinib for moderate to severe atopic dermatitis with generalized prurigo nodularis

被引：0
|
作者：
Lou, Fanglu [1 ,2 ,3 ,4 ]
Wang, Yuyi [1 ,2 ,3 ,4 ]
Xiao, Yujuan [1 ,2 ,3 ,4 ]
Liu, Yi [1 ,2 ,3 ,4 ]
机构：
[1] Chongqing Coll Tradit Chinese Med, Affiliated Hosp 1, Dept Dermatol, Chongqing 400011, Peoples R China
[2] Chongqing Hosp Tradit Chinese Med, Dept Dermatol, 40 Daomenkou St, Chongqing 400011, Peoples R China
[3] Chongqing Key Lab Integrat Dermatol Res, Chongqing, Peoples R China
[4] Chongqing Clin Res Ctr Dermatol, Chongqing, Peoples R China
来源：
ASIAN JOURNAL OF SURGERY | 2024年 / 47卷 / 07期
基金：
中国国家自然科学基金;
关键词：
D O I：
10.1016/j.asjsur.2024.02.127
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
引用
收藏
页码：3084 / 3088
页数：5
相关论文
共 50 条
  • [41] Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab
    Deng, Junwen
    Liao, Viviane
    Parthasarathy, Varsha
    Cornman, Hannah L.
    Kambala, Anusha
    Kwatra, Madan M.
    Stander, Sonja
    Piketty, Christophe
    Chaskar, Prasad
    Krishnaswamy, Jayendra Kumar
    Julia, Valerie
    Kwatra, Shawn G.
    JAMA DERMATOLOGY, 2023, 159 (09) : 977 - 985
  • [42] Effectiveness of upadacitinib in Japanese patients with prurigo-type atopic dermatitis: Four cases report
    Kosaka, Keiji
    Uchiyama, Akihiko
    Ishikawa, Mai
    Motegi, Sei-ichiro
    JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2023, 6 (06) : 262 - 263
  • [43] Efficacy and safety of upadacitinib for the treatment of moderate-to-severe atopic dermatitis: a systematic review and meta-analysis
    Huang, Yuanjie
    Cai, Limin
    Wu, Xuerui
    Chen, Chen
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2023, 40 (06): : 725 - 733
  • [44] Network meta-analysis on the efficacy and safety of upadacitinib in adolescents and adults with moderate-to-severe atopic dermatitis
    Qiu, Mei
    Duan, Xue-Yan
    Yin, Dao-Gen
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 2022, 61 (01) : E24 - E26
  • [45] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis A Randomized Clinical Trial
    Blauvelt, Andrew
    Teixeira, Henrique D.
    Simpson, Eric L.
    Costanzo, Antonio
    De Bruin-Weller, Marjolein
    Barbarot, Sebastien
    Prajapati, Vimal H.
    Lio, Peter
    Hu, Xiaofei
    Wu, Tianshuang
    Liu, John
    Ladizinski, Barry
    Chu, Alvina D.
    Eyerich, Kilian
    JAMA DERMATOLOGY, 2021, 157 (09) : 1047 - 1055
  • [46] Upadacitinib for Patients with Atopic Dermatitis
    不详
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2022, 147 (09) : 506 - 506
  • [47] Dramatic improvement of generalized prurigo nodularis with dupilumab
    Calugareanu, A.
    Jachiet, M.
    Lepelletier, C.
    De Masson, A.
    Rybojad, M.
    Bagot, M.
    Bouaziz, J. D.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2019, 33 (08) : E303 - E304
  • [48] Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
    Smith, Brandon I.
    Engel, Priya
    Wu, Jashin
    NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (24): : 2299 - 2300
  • [49] Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
    Sheridan M. Hoy
    American Journal of Clinical Dermatology, 2022, 23 : 409 - 420
  • [50] Treatment options for moderate to severe atopic dermatitis
    Wallace, Dana V.
    ALLERGY AND ASTHMA PROCEEDINGS, 2022, 43 (06) : 474 - 493
12345